Results 181 to 190 of about 25,689,350 (343)
Consensus molecular subtypes (CMS1‐4) have been identified to study colorectal cancer heterogeneity and serve as potential biomarkers. In this study, we developed and evaluated NanoCMSer, a NanoString‐based classifier using 55 genes, optimized for FF and FFPE to facilitate the clinical evaluation of CMS subtyping.
Arezo Torang+10 more
wiley +1 more source
Review of the edited volume: Sandra Calkins, Enrico Ille, and Richard Rottenburg (eds), Emerging Orders in the Sudans, Bamenda and Buea: Langaa RPCIG, 2015, ISBN 9956792160, 294 pp.
Annette Weber
doaj
Tumor microenvironment drives cancer formation and progression. We analyzed the role of human cancer‐associated adipocytes from patients with renal cell carcinoma (RCC) stratified as lean, overweight, or obese. RNA‐seq demonstrated that, among the most altered genes involved in the tumor–stroma crosstalk, are ADAM12 and CYP1B1, which were proven to be ...
Sepehr Torabinejad+13 more
wiley +1 more source
Review of the monograph: Jenny Kuhlmann, Transnational Diaspora Politics: Cross-Border Political Activities of Zimbabweans in the United Kingdom, Leipzig: Leipziger Universitätsverlag, 2013, ISBN 9783865837417, 412 ...
Brian Raftopoulos
doaj
Large multidimensional digital images of cancer tissue are becoming prolific, but many challenges exist to automatically extract relevant information from them using computational tools. We describe publicly available resources that have been developed jointly by expert and non‐expert computational biologists working together during a virtual hackathon
Sandhya Prabhakaran+16 more
wiley +1 more source
ON THE PRESENT STATE OF KNOWLEDGE AS TO THE STRENGTH AND RESISTANCE OF MATERIALS. [PDF]
J Gaudard
openalex +1 more source
The authors conducted a retrospective study of 94 patients with advanced cancer who underwent next‐generation sequencing (NGS) gene panel analysis and received targeted treatments when applicable. Results further support evidence indicating that molecular profiling provides clinical benefit.
Michaël Dang+3 more
wiley +1 more source
Analysis of ESR1 mutations in plasma cell‐free DNA (cfDNA) is highly important for the selection of treatment in patients with breast cancer. Using multiplex‐ddPCR and identical blood draws, we investigated whether circulating tumor cells (CTCs) and cfDNA provide similar or complementary information for ESR1 mutations.
Stavroula Smilkou+11 more
wiley +1 more source